Global segment ranking · Healthtech › Access to care

The world’s most valuable online pharmacies

E-pharmacies and digital pharmacies whose main activity is selling and delivering prescription and over-the-counter medicines. Ranked worldwide by AI-estimated valuation. The market sets the value; our AI estimates it.

Edition 0 (beta) · Published September 29, 2026 Twice a yearNext edition: January 1, 2027· Claude · multi-AI consensus in a future edition· Published method· Order never changed by a human

Key metrics for this segment: customers / prescriptions, revenue, profit. Figures as published by each company or the press, dated, not recalculated. The AIs weigh them alongside funding history and comparables.

Not in this segment. Telemedicine, appointment booking, mental health and women's health platforms each have their own segment, even when they dispense medication. A company appears in one segment only. Method

The segment at a glance

6companies ranked

2companies on the radar

4countries in the ranking

6listed benchmarks

Sources: TechCrunch, Entrackr, Inc42, Business Standard, Forge Global, The Information, Axios, TechPoint Africa, StartupList Africa, Dabafinance, company announcements. Intention counters will be shown above a threshold of amount and number of Backers.

Rankings by region

Filter the ranking and the Radar. Ranks stay worldwide.

Global ranking · Online pharmacy

Top 6 Radar Challengers

First edition: no movements yet.

World · 6 ranked companies

#	Company	Last round · Key metrics	Estimated valuation (AI, order of magnitude)	Confidence	Invest
1	Blink HealthUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series D · about USD 140M (Series D and C-1 combined) · Nov 2024Key metrics not disclosed	Last known equity round: Series D · about USD 140M (Series D and C-1 combined) · Nov 2024 (incl. 1789 Capital, 8VC, Fidelity) Published valuation: USD 1.96B post-money (Forge Global) (Nov 2024) Confidence index: MediumMethod	Partial sources	Declare an intent
2	PharmEasyIndia · Asia-PacificSources: 1 · 2 · 3Is this your company? Report an error	Rights issue · USD 216M · Apr 2024Customers / prescriptions: n/d · Revenue ₹5,872 Cr (~$690M) operating revenue · Net loss ₹1,572 Cr · FY2025	Last known equity round: Rights issue · USD 216M · Apr 2024 (existing shareholders) Published valuation: USD 456M implied by an investor's fund mark (Dec 2024) Confidence index: MediumMethod	Partial sources	Declare an intent
3	TruemedsIndia · Asia-PacificSources: 1 · 2Is this your company? Report an error	Series C · USD 85M (USD 65M primary, USD 20M secondary) · Aug 2025500,000 monthly active customers; 3M customers served (2025) · Revenue ₹500 Cr (~$57M) (FY2025) · Net loss ₹61 Cr (FY2024)	Last known equity round: Series C · USD 85M (USD 65M primary, USD 20M secondary) · Aug 2025 (led by Accel and Peak XV, with WestBridge and Info Edge Ventures) Published valuation: over USD 400M (Aug 2025) Confidence index: HighMethod	Solid sources	Declare an intent
4	CapsuleUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series E · USD 100M · Feb 2023Key metrics not disclosed	Last known equity round: Series E · USD 100M · Feb 2023 (incl. Cox Enterprises, Seedford Partners) Published valuation: USD 458M post-money (Forge Global) (Feb 2023) Confidence index: MediumMethod	Partial sources	Declare an intent
5	mPharmaGhana · Sub-Saharan AfricaSources: 1 · 2Is this your company? Report an error	Venture round · undisclosed (previous: USD 30M Series D, Jan 2022) · Nov 2025Key metrics not disclosed	Last known equity round: Venture round · undisclosed (previous: USD 30M Series D, Jan 2022) · Nov 2025 (not disclosed) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
6	YodawyEgypt · Middle East & North AfricaSources: 1 · 2Is this your company? Report an error	Growth equity · USD 10M · Jan 2024~200,000 prescriptions per month; 50,000+ recurring chronic patients · Revenue: n/d · Profit: n/d · Feb 2023	Last known equity round: Growth equity · USD 10M · Jan 2024 (Ezdehar Mid-Cap Fund) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent

Ranking in descending order of AI-estimated valuation, based on public information, following a published method, with no human intervention on the order. Valuation ranges are indicative editorial estimates: neither a financial valuation, nor an offer, nor investment advice. Only the market sets a company’s value, through a funding round or a sale. Edition 0: produced by Claude (Anthropic); a consensus of several AI models will apply in a future edition. Eligibility: at least $1M raised including one equity round, non-listed company, main activity in this segment (online sale and delivery of prescription and over-the-counter medicines). Country shown is the country of main operations. Request a correction

Get every new edition

New entries, exits and movements, twice a year.

One e-mail per edition. One-click unsubscribe. No data passed on to third parties.

How to read this ranking

Rank

Companies are ranked by AI-estimated valuation, highest first. The market sets the value; our AI estimates it.

Range

An order of magnitude, never a figure.

Hundreds of k$
Millions $
Tens of M$
Hundreds of M$
Unicorn
Decacorn

Confidence

High: recent published valuation or round (under 24 months).
Medium: older data.
Low: single or unconfirmed source.

Full method →

Invest in online pharmacy, together

Uback aggregates investment intentions from business angels, family offices, corporates and sector specialists worldwide. Every ranked company already has professional investors on its cap table, who have negotiated a shareholders’ agreement: you don’t start from a blank page.

Strength in numbers

Alone, a small ticket opens no doors. Together, Backers carry weight.

Declare an intention

On a company or a sector, with a ticket range. Paid, to show you are serious; transferable as long as it has not been converted.

Critical mass is reached

When the number of Backers and the total of their intentions cross a threshold, the licensed partner contacts the company and presents this demand.

The licensed partner structures

If the company’s expectations and the Backers’ converge, the partner builds a transaction and presents it directly to the Backers concerned.

Closing

Capital raise or sale of existing shares: small tickets are pooled in a common vehicle set up by the licensed partner. Each Backer decides whether to take part.

Uback does not advise, does not negotiate, collects nothing. Each transaction is run by the licensed partner of the company’s country, under the law that governs its shares.

Get notified when intentions open What happens after my declaration? Intention declarations open once the licensed partner signs · price per ticket band · valid 12 months · transferable credit

Challengers

A registered company raising funds that is not in the ranking will be able, for a fee, to appear in a separate list labelled “Challengers”, for a set period, with a memo available to verified Backers. The listing has no effect on the ranking. Not open yet.

Sponsored space · no Challenger listed yet

Radar · known eligible companies, not ranked

Sorted by date of last round, with no judgement and no AI call.

Chefaa · Egypt · Middle East & North AfricaDec 2023 · USD 5.2M
Medino · United Kingdom · EuropeOct 2020 · USD 7.3M

Listed benchmarks

Not ranked: no intention is possible on a listed company.

Redcare Pharmacy · GermanyXETRA · RDC
DocMorris · SwitzerlandSIX · DOCM
JD Health · ChinaHKEX · 6618
Alibaba Health · ChinaHKEX · 0241
111 Inc · ChinaNASDAQ · YI
GoodRx · United StatesNASDAQ · GDRX

Sources and method for this segment

Calendar. Global segment rankings are published twice a year. Next edition: January 1, 2027.

Eligibility. At least $1M raised including one equity round, non-listed company, main activity in this segment (online sale and delivery of prescription and over-the-counter medicines). A company appears in one segment only.

Sources. TechCrunch, Entrackr, Inc42, Business Standard, Forge Global, The Information, Axios, TechPoint Africa, StartupList Africa, Dabafinance, company announcements.

Method and rules, common to all rankings →